Abstract
Recent European Guidelines for Diabetes, Prediabetes and Cardiovascular Diseases introduced a shift in managing patients with type 2 diabetes at high risk for or established cardiovascular (CV) disease by recommending GLP-1 receptor agonists and SGLT-2 inhibitors as initial glucose-lowering therapy. This is questioned since outcome trials of these drug classes had metformin as background therapy. In this post hoc analysis, the effect of dulaglutide on CV events was investigated according to the baseline metformin therapy by means of a subgroup analysis of the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. Patients in REWIND (n = 9901; women: 46.3%; mean age: 66.2 years) had type 2 diabetes and either a previous CV event (31%) or high CV risk (69%). They were randomized (1:1) to sc. dulaglutide (1.5 mg/weekly) or placebo in addition to standard of care. The primary outcome was the first of a composite of nonfatal myocardial infarction, nonfatal stroke, and death from cardiovascular or unknown causes. Key secondary outcomes included a microvascular composite endpoint, all-cause death, and heart failure. The effect of dulaglutide in patients with and without baseline metformin was evaluated by...Continue Reading
References
Apr 23, 2008·Circulation·Kiwon BanMansoor Husain
Jun 13, 2015·European Heart Journal·Ele Ferrannini, Ralph A DeFronzo
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Apr 14, 2017·The New England Journal of Medicine·Aidin RawshaniSoffia Gudbjörnsdottir
Jun 3, 2017·Diabetes, Obesity & Metabolism·Hertzel C GersteinUNKNOWN REWIND Trial Investigators
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Aug 5, 2017·Diabetologia·Simon J GriffinGreg J Irving
Oct 13, 2017·Cardiovascular Diabetology·Oliver SchnellUNKNOWN D&CVD EASD Study Group
May 21, 2018·Biochimica Et Biophysica Acta. Molecular Basis of Disease·Manfredi RizzoFrancesco Cosentino
Oct 7, 2018·Lancet·Adrian F HernandezUNKNOWN Harmony Outcomes committees and investigators
Nov 13, 2018·The New England Journal of Medicine·Stephen D WiviottUNKNOWN DECLARE–TIMI 58 Investigators
Dec 14, 2018·Cardiovascular Diabetology·Andrei C SpositoJosé Francisco Kerr Saraiva
Feb 5, 2019·Diabetes, Obesity & Metabolism·Kristina S BoyeMark C Lakshmanan
Jun 12, 2019·The New England Journal of Medicine·Mansoor HusainUNKNOWN PIONEER 6 Investigators
Jun 14, 2019·Lancet·Hertzel C GersteinUNKNOWN REWIND Investigators
Sep 10, 2019·European Heart Journal·Francesco CosentinoUNKNOWN ESC Scientific Document Group
Dec 4, 2019·Diabetes, Obesity & Metabolism·Silvio E InzucchiUNKNOWN EMPA-REG OUTCOME® Investigators
Dec 21, 2019·Diabetes Care·John B BuseMelanie J Davies
Feb 10, 2020·Diabetes Research and Clinical Practice·Eberhard Standl, Oliver Schnell
Jul 11, 2020·Diabetes Care·Matthew J CrowleyJohn B Buse
Citations
Nov 18, 2020·European Heart Journal·Naveed Sattar, Darren K McGuire
Sep 15, 2021·Diabetes, Obesity & Metabolism·Christine Rode AndreasenTina Vilsbøll
Aug 15, 2021·Cardiovascular Research·Gianluigi SavareseStefan D Anker